Early recombinant human epidermal growth factor treatment recovers the irradiation-induced decrease of Na+ absorption prior to the definite histological mucositis.
Recombinant human epidermal growth factor (rhEGF) has potential benefit for the mucositis induced by radiation therapy as a therapeutic setting. In this study, we aimed to investigate the effects of rhEGF treatment on the radiation-induced changes in epithelial transport function, before the occurrence of the definitive histological mucosal changes. C3H/He mice received 0, 4, or 8 Gy irradiation and/or EGF treatment (rhEGF 0, 1 and 5mg/kg, i.p., 5 days). At day 7, we recorded short circuit current (I(sc)) of the upper tracheal epithelium using the flow-type Ussing chamber method, with histological analysis. As a result, there was no evident pathological change in the epithelium from the irradiated and/or rhEGF treated mice at day 7. The initial level of I(sc) and amiloride-sensitive I(sc) (ΔI(sc,Amil)) were decreased after 8 Gy irradiation, reflecting suppression of basal Na+ absorption. The decreased ΔI(sc,Amil) was recovered by rhEGF treatment. In conclusion, epithelial Na+ channel-dependent basal Na+ absorption was primarily affected by irradiation, before the pathological changes. The recovery of basal Na+ absorption (ΔI(sc,Amil)) suggested a potentially beneficial effect of early rhEGF treatment for irradiation-induced suppression of the upper aerodigestive epithelial functions.
Kim
Jin Kyoung
JK
Department of Anesthesiology-Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Kim
Chung Su
CS
Ahn
Hyun Joo
HJ
Bang
Si Ra
SR
Kim
Sung Joon
SJ
Yoo
Hae Young
HY
Jeong
Han-Sin
HS
D000042:Absorption / Q000187:drug effects*; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D004815:Epidermal Growth Factor / Q000494:pharmacology / Q000627:therapeutic use*; D004848:Epithelium / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D005260:Female; D006801:Humans; D017136:Ion Transport / Q000187:drug effects; D051379:Mice; D008809:Mice, Inbred C3H; D052016:Mucositis / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D011833:Radiation Injuries, Experimental / Q000188:drug therapy*; D011837:Radiation-Protective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D012964:Sodium / Q000378:metabolism*; D014132:Trachea / Q000187:drug effects / Q000378:metabolism / Q000473:pathology
D011837:Radiation-Protective Agents; D011994:Recombinant Proteins; D004815:Epidermal Growth Factor; D012964:Sodium